New York, April 06, 2016 (GLOBE NEWSWIRE) -- Provista Diagnostics Inc., a company developing and commercializing molecular diagnostic, prognostic and monitoring tests for cancers affecting women, has promoted Uriel Kusiatin, M.B.A. to Chief Financial Officer and Kelly Gordon, Ph.D., MB (ASCP CM), to Vice President of Research and Development. Additionally, the company has filled senior positions on the rapidly expanding commercial team, with Doug Bradley, M.B.A. joining as Vice President of Global Marketing, and Wendy Ross Morray joining as Senior Director of Reimbursement.
“Uriel Kusiatin has been an important partner to Provista Diagnostics since he began consulting with the company in 2013 and formally joined in 2015 as Senior Vice President of Finance. During his tenure, he has provided strategic guidance, performed critical financial planning and analysis and developed robust financial systems and processes that have positioned the company for successful growth and commercialization of our pipeline diagnostics,” said David E. Reese, Ph.D., President and Chief Executive Officer of Provista. “Kelly Gordon’s new role will be pivotal in leveraging Provista’s ProteoMark® technology to close important diagnostic gaps in cancers that affect women. Her experience in prior positions, such as Roche, is already resulting in significant value creation. The expansion of our commercial team, with the addition of Doug Bradley and Wendy Ross Morray will be invaluable as we commercialize Videssa® Breast and broadly introduce this first-of-its-kind diagnostic to physicians, patients and payers.”
Mr. Kusiatin began his career at Deloitte and has dedicated the past 25 years to helping companies solve significant business and financial challenges. He has overseen strategy development, operational execution and financial management at numerous companies in the life sciences industry. He has also advised large international pharmaceutical, biotech and medical device companies, as well as start-up companies. Mr. Kusiatin holds a Bachelor of Science in Industrial Engineering from the Technical Institute of Denmark and a Master of Business Administration from the Wharton School of the University of Pennsylvania.
Dr. Gordon joined Provista in 2015 as Director of Clinical Development. Prior to Provista, Gordon served as the CDx Regulatory Affairs Manager for Roche Tissue Diagnostics where she was the contact for a cross-functional team of biostatisticians, clinical affairs managers, data managers, development scientists, manufacturing personnel, marketing managers, pathologists, project managers and quality engineers and managed companion diagnostics projects for oncology drugs at all stages of development. Dr. Gordon holds a Bachelor of Science in Molecular and Cellular Biology from the University of Arizona and a Doctor of Philosophy and Pharmacology from Duke University.
Mr. Bradley joins Provista from Caris Life Sciences, where he served as Vice President of Marketing. Prior to Caris, he held the position of Executive Vice President of Global Marketing at Agendia, a molecular diagnostic company that develops and markets genomic assays for early stage breast cancer. He brings extensive experience in marketing in an array of diagnostics, medical devices, and capital equipment for businesses ranging from Fortune 500 market leaders to start-up companies and high-growth enterprises. Mr. Bradley holds a Bachelor of Science in Microbiology from the University of Oklahoma and a Master of Business Administration from Pepperdine University.
Ms. Morray joins Provista from Prometheus Laboratories Inc. where she served as the Director of Coding and Reimbursement. She has more than 35 years of experience managing coverage and reimbursement strategy, including consulting to laboratories developing and using new technologies. In this capacity, she has advised on reimbursement models given evolving industry and regulatory trends and has helped develop patient assistance programs. She holds a Bachelor of Arts in Biology from Goucher College.
In addition to filling these key leadership positions, Provista has also continued building its sales team and has hired four senior sales representatives in 2016.
About Provista Diagnostics, Inc.
Provista Diagnostics is a privately held molecular diagnostics company headquartered in New York focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in cancers affecting women, such as breast and gynecologic cancers. Provista Diagnostics’ state-of-the-art, high complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).
Additional information about Provista Diagnostics is available at ProvistaDx.com
Information about Provista Diagnostics’ clinical trials is available at ClinicalTrials.gov
Safe Harbor Statement
Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista’s actual results may differ materially due to a number of factors, many of which are beyond Provista’s ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.
Susan LaMacchia 212-202-3174 PR@ProvistaDx.com
Source:Provista Diagnostics, Inc.